Indication
- for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy
- as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer
Medicine details
- Medicine name:
- degarelix (Firmagon)
- SMC ID:
- SMC2625
- Pharmaceutical company
- Ferring Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Publication due date:
- 11 December 2023